Background: Fibrinogen-like protein 2 (FGL2) may promote glioblastoma multiforme (GBM) cancer development by inducing multiple immune-suppression mechanisms.
Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans and even with aggressive surgery, radiation, and chemotherapy has a median survival of only 14.6 months (1). In GBM, the presence of multiple, redundant immune-suppressive mechanisms, such as immunosuppressive cells (CD4   +   CD25 + FoxP3 + regulatory T cells [Treg] , tumor-supportive M2 macrophages, and myeloid-derived suppressor cells [MDSCs] ), immunosuppressive cytokines (TGF-β, IL-10 and PGE2), and immune checkpoints (PD-L1, PD-1, and CTLA-4), reduces the efficiency of immunotherapy (2) (3) (4) (5) (6) (7) . Monoclonal antibodies (mAbs) targeting immune checkpoints are now a standard of care for melanoma patients (8) ; however, these mAbs must be combined with other immunotherapeutic strategies to suppress glioma growth in preclinical murine article models (7, 9, 10) . Clinical studies of checkpoint inhibitors are underway in GBM patients (11) , but the success of immunotherapy will depend upon in-depth understanding of immunology in the brain and GBM microenvironment to unveil the key regulatory hubs of immunosuppressive mechanisms.
Fibrinogen-like protein 2 (FGL2), a member of the fibrinogen-like protein family, possesses prothrombinase activity and immune regulatory functions in viral infection, allograft rejection, and abortion (12, 13) . Some investigators have suggested that FGL2 acts as a Treg effector molecule by suppressing T-cell activities in a FoxP3-dependent manner (14, 15) . Others have found that FGL2 suppresses dendritic cell (DC) and B cell functions by binding to FcγRIIB (16, 17) . Furthermore, emerging data demonstrates that FGL2 regulates adaptive immunity via Th1 and Th2 cytokines (18) . Recent studies have also shown that FGL2 can promote hepatocellular carcinoma xenograft tumor growth and angiogenesis, suggesting a tumor-promoting function (19, 20) . However, these studies were conducted in immunedeficient mice, which does not account for the immune regulatory role of FGL2 in tumor progression (19, 20) .
Both murine glioma models and human glioma patient samples were used to test the hypothesis that FGL2 might promote GBM by inducing immune suppression mechanisms in the tumor microenvironment. These studies revealed that FGL2 increases glioma growth in murine models by enhancing immune checkpoint gene expression and infiltration of immunosuppressive cells in the tumor microenvironment. Neutralization of the FGL2 protein by an anti-FGL2 antibody prolonged survival time in immune-competent mice harboring GL261 gliomas, but this effect was abolished in immune-deficient NSG mice. Consistent with the hypothesis that FGL2 may play a role in GBM progression, the expression levels of FGL2 positively correlated with glioma grade in patients. Collectively, these data show that FGL2 can function as a promoter of GBM progression by upregulating negative immune checkpoint expression and may be a therapeutic target.
Methods

cBioPortal for Cancer Genomics
Gene expression data and survival were obtained from the The Cancer Genome Atlas (TCGA) portal (http://www.cbioportal.org/ public-portal/Accessed May 1, 2015) (see Figure 1 legend ). Pearson's correlation coefficients were calculated between the immune checkpoints/cytokines and FGL2 gene expression using R statistical computing (21) .
Human Samples
Sample collection was conducted under protocol #LAB03-0687, which was approved by the institutional review board of The University of Texas M.D. Anderson Cancer Center (M.D. Anderson) after informed consent was obtained. Patients' tumors with matched serum samples were graded pathologically (n = 20) by a neuropathologist according to the World Health Organization classification (22) .
Gene Constructs and Transfection
The pBMN-GFP and pBMN-FGL2 expression vectors were constructed by standard subcloning procedures (23) . Transfection gene in tumors from the low-grade glioma (n = 262) and glioblastoma multiforme (n = 136) databases. These levels are derived from the GISTIC copy-number analysis algorithms and indicate the copy-number level per gene. Chi-square test: P < .001. B) The overall survival rates of GBM patients were stratified by FGL2 gene expression levels. Data on survival of GBM patients and FGL2 mRNA expression data were downloaded and retrieved from the The Cancer Genome Atlas data portal (https://tcgadata.nci.nih.gov/tcga/dataAccessMatrix.htm Accessed May 1, 2015). GBM patients were grouped by FGL2 gene expression level: the 50% of patients top ranked for FGL2 levels were placed in the FGL2 High group and the lowest ranked 50% of patients in the FGL2 Low group. FGL2 = Fibrinogen-like protein 2. article was carried out using lipofectamine 2000 according to the manufacturer's instructions (Invitrogen). Stable clones were obtained using puromycin selection for two weeks (22) . Further details are provided in the Supplementary Methods (available online).
Animals
C57BL/6J, BALB/c, and NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) female mice from the Jackson Laboratory, and FcɣRIIB-/-mice from Taconic Biosciences, all age six to eight weeks, were used in the experimental procedures. All mice were maintained and were treated in accordance with the guidelines approved by the Institutional Animal Care and Use Committee (IACUC). Further details are provided in the Supplementary Methods (available online).
Flow Cytometry
Tumor or brain tissues were minced and enzymatically digested to obtain single cell suspensions (24, 25) . Brain-infiltrating lymphocytes were isolated according to previously published protocol (26) . Briefly, a single-cell suspension was centrifuged through a 30% Percoll gradient at 7800 g for 30 minutes. The lymphocyte layer was collected, centrifuged, and washed. Cell surface staining was performed with FITC, PerCP/Cy5.5, or Brilliant Violet 421-labeled anti-CD4, anti-CD25, anti-CD11b, anti-F4/80, anti-Gr1.1, anti-PD-L1, anti-PD-1, anti-CD39, anti-CD206, and anti-CD45 Abs (mouse monoclonal, 1:50, BioLegend, California) (26, 27) . For intracellular staining, cells were fixed and permeabilized, and then incubated with PerCP/Cy5.5-labled anti-Foxp3 antibody (mouse monoclonal, 1:25, BioLegend, California). Stained cells were analyzed with flow cytometry, and the data were presented using FlowJo software.
Statistical Analysis
All quantified data are presented as mean ± standard deviation or as indicated. Differences in the experimental means for flow cytometric and cytokine values were considered statistically significant if P values were less than .05 as determined using unpaired t test. Differences in the distribution of FGL2 gene copy number in the human gliomas were considered by chi-square analysis at P values under .05. Associations between the FGL2 level and clinic pathological characteristics were analysed by Fisher's exact test. A two way analysis of variance (ANOVA) was used to analyze tumor volume difference between groups. Differences in survival curves were considered statistically significant by the log-rank survival analysis at P values under .05. glioblastoma patients (n = 13) and low-grade glioma patients (n = 7) using an enzyme-linked immunosorbent assay (ELISA) kit. Data were presented as the mean ± SD.
An unpaired t test was used to calculate the two-sided P values.
Downloaded from https://academic.oup.com/jnci/article-abstract/107/8/djv137/946327 by guest on 07 December 2018 article All statistical analyses were conducted using GraphPad Prism 6 (GraphPad Software, La Jolla, CA), except for the Pearson's correlation coefficients, which were performed by SPSS version 22 (IBM Corporation, Armonk, NY). All statistical tests were two-sided.
Results
Association of FGL2 Expression With Glioma Grade and Poor Prognosis in GBM
The TCGA database was used to evaluate the association between the gene copy number of FGL2 and glioma grade. In low-grade gliomas, 72.5% of patients maintained two copies of the FGL2 gene (diploid), whereas 83.8% of GBM patients had either a gene amplification or copy gain ( Figure 1A) high patients. The expression levels of FGL2 protein in three human glioblastoma cell lines (LN18, U87, and U251) and three glioblastoma cancer stem cell lines (gCSC13, gCSC811, and gCSC929) were also higher than in fibroblast cell lines (MRC5 and WI38) (Figure 2A) . To investigate the expression status of FGL2 in human gliomas, seven low-grade glioma tumors and 13 GBMs were collected and analyzed ( Figure 2B ). Consistent with the data found in tumor cells, the levels of FGL2 protein in GBM tumors were statistically higher relative to low-grade gliomas (mean ± SD: 11.48 ± 5.75 ng/ mg vs 3.96 ± 1.01 ng/mg, P = .003). Further investigation into the association of FGL2 level with clinicopathological characteristics of patients revealed that the levels of FGL2 protein in glioma lysates were statistically significantly associated with tumor grade (P = .003, Fisher's exact test) ( Table 1 ) but not tumor size or patient sex. Likewise, an increased level of Fgl2 was also detected in GBM patients compared with low-grade glioma patients or healthy donors (mean ± SD: 46.9 ± 20.1 ng/mL vs 37.4 ± 21.5 ng/ 
FGL2 and Glioma Tumor Growth
To ascertain the functional role of FGL2 in glioma biology, the effect of FGL2 expression levels on tumor growth kinetics was studied. Unlike human GBM, murine glioma cell lines express low levels of FGL2 protein when cultured in vitro ( Figure 3A) ; therefore, delayed brain tumor (DBT) glioma cells were genetically engineered to express FGL2 while GFP-expressing DBT cells were used as a control cell line (mean ± SD: 6.9 ± 1.7 vs 1.0 ± 0.0, P = .03) ( Figure 3A) . The FGL2-engineered DBT cells (DBT-FGL2) secreted 68 ng/mL of FGL2, whereas FGL2 was undetectable in the control cells. Serum FGL2 was elevated in mice harboring DBT-FGL2 cells relative to DBT-GFP cells (mean ± SD: 44.5 ± 5.7 ng/mL vs 35.4 ± 1.3, P = .02) ( Figure 3B ). Correspondingly, DBT-FGL2 had an increased growth rate relative to DBT-GFP in vivo (Figure 3 , C-E) although the proliferation rates in vitro were the same ( Figure 3F ). Consistent with the larger tumor volume, DBT-FGL2 tumors had more mass than DBT-GFP tumors at the completion of the experiment (0.10 ± 0.02 vs 0.33 ± 0.14 g, P = .04) ( Figure 3E) . Importantly, the difference in tumor progression between DBT-FGL2 and DBT-GFP cells no longer exists in immune-deficient NSG mice (Figure 3, G-I ).
FGL2 as an Immunosuppressive Hub
To determine if FGL2 exerts multimodality modulation of GBMmediated immune suppression, the expression of FGL2 was correlated with immune checkpoints (PD-1, PD-L1, CTLA-4), CD39, B-and T-lymphocyte attenuator (BTLA), lymphocyte-activation gene 3 (LAG3), transforming growth factor-β1 (TGF-β1), and interleukin-10 (IL-10) by applying Pearson's correlation analysis (Figure 4) . Except for CTLA-4 (P = .67) (Figure 4G ), there is a statistically significant positive correlation between FGL2 expression and PD-L2 ( Figure 4B ), PD-1 ( Figure 4C ), CD39 ( Figure 4D ), BTLA ( Figure 4E ), LAG3 ( Figure 4F ), IL-10 ( Figure 4I ), and TGFβ1 ( Figure 4H ) (correlation is statistically significant at a P value of .01 [two-tailed]).
To validate the observed correlations from humans specimens, the murine subcutaneous gliomas generated by DBT-FGL2 and DBT-GFP were used to ascertain if similar assocations were + population (M2) (27, 28) in the tumor microenvironment ( Figure 5B ), which may indicate that FGL2 facilates M2 polarization in tumors. Together, these data show that FGL2 augments immunosuppression in the tumor microenvironment.
Next, the association between FGL2 overexpression and increased immunosuppression was determined in an orthotopic brain tumor model. Tumors developing from FGL2-overexpressing GL261 glioma cells had increased PD-1 and CD39 expression in CD45 + leukocytes relative to those from GL261-GFP control tumors ( Figure 6A) . Additionally, the frequency of MDSC and M2 cells was markedly increased in brain-infiltrating lymphocytes in mice inoculated with GL261-FGL2 cells compared with those inoculated with GL261-GFP control cells ( Figure 6B ), indicating that FGL2 induces immune suppression regardless of the in vivo location.
FcγRIIB is the receptor of FGL2 (17); thus, FcγRIIB -/-mice were used to investigate the dependence of the Fgl2-FcγRIIB signaling axis on producing FGL2-mediated immunosuppression in glioma. Indeed, the absence of FcγRIIB impeded the induction of CD39 and PD-1 expression ( Figure 6C ) and totally abolished the presence of M2 cells by FGL2 in the glioma microenvironment ( Figure 6D ). However, there was still an increase of CD39 + Tregs and the MDSC population in the GL261-FGL2 tumors relative to GL261-GFP tumors in FcγRIIB -/-mice ( Figure 6D ). These data suggest that the CD39 and PD-1 expression and M2 polarization induced by FGL2 are mediated by the FcγRIIB pathway, whereas MDSC and Treg induction by FGL2 likely does not depend on the FcγRIIB signal pathway.
Effect of Blocking FGL2 on Survival of GL261 GliomaBearing Mice and Immunosuppression
At baseline, nontreated, non-tumor bearing mice express FGL2 in the serum at only 29.5 ± 2.59 ng/mL; however, glioma-bearing mice regardless of treatment with control IgG or anti-FGL2 antibody have statistically significantly increased FGL2 levels in the serum (mean ± SD: 53.8 ± 9.53 and 56.5 ± 5.78 ng/mL, respectively) ( Figure 7A ). To test if a first-generation FGL2 antibody could exert a proof-of-principal therapeutic effect, immune-competent C57BL/6 mice harboring intracerebral GL261 gliomas were treated twice per week and monitored for survival. The median survival time was statistically significantly longer in mice treated with an anti-FGL2 antibody relative to those treated with an IgG control antibody (27 days and 17 days, respectively, P = .01) ( Figure 7B ). Interestingly, four of seventeen anti-FGL2-treated mice (23.5%) were completely tumor free. Furthermore, the anti-FGL2 antibody treatment suppressed M2 and MDSC accumulation as well as CD39 and PD-1 induction (Figure 7, C-F) , though the FGL2 antibody treatment did not statistically significantly reduce the level of FGL2 in the serum, suggesting that FGL2 antibody blocked the function of FGL2 in these mice. Collectively, the results show that FGL2 is a potential therapeutic target for treating GBM. 
Discussion
FGL2 has previously been shown to be upregulated in a number of other human malignancies (12, 19, 29) . This report is the first showing that FGL2 is commonly expressed in human gliomas and FGL2 expression is associated with glioma grade. Previously, FGL2 had been shown to promote Treg activities, suppress Th1 and enhance Th2 skewing, and downregulate antigen presentation activity (16, (30) (31) (32) (33) . This report markedly expands these findings to show that FGL2 also regulates immune checkpoints and augments intratumoral MDSC and M2 skewing. More specifically, FGL2 induces CD39 expression in CD45 + lymphocytes within the tumor microenvironment. The induction of CD39 is important because CD39 ultimately converts ATP to adenosine (34, 35) , which is a potent suppressor of T cell activation and effector function (36) . Furthermore, CD39 can enhance the conversion of M1 into tumor-promoting M2 tumor-associated macrophages (37) and augment tumor supportive activities of MDSC (38) . The reduction of CD39 expression in FcγRIIB-/-mice was associated with the article suppression of FGL2-mediated M2 accumulation in the glioma. Tumor-associated macrophages frequently exhibit an M2 phenotype that supports angiogenesis and invasiveness in tumors (6, 39, 40) . Blocking M2 polarization with the inhibitor CSF-1R has been shown to suppress glioma growth (6) . The data show that targeting FGL2-induced M2 polarization is a viable therapeutic approach. Alternatively, FGL2 could mediate M2 polarization secondarily via modulation of Th2 cytokine elaboration (41) . FGL2 can suppress production of the Th1 cytokines IL-2 and IFN-γ while enhancing Th2 cytokines such as IL-4 and IL-10 (18). FGL2 -/-mice express high levels of Th1 cytokines, such as IFN-γ, and low levels of the Th2 cytokine IL-4 (33) . Of course, FGL2 may induce M2 polarization by both aforementioned mechanisms and this hypothesis will be tested in the future.
Besides modulating M2 polarization, FGL2 also exerts multimodality effects on immune checkpoints, MDSCs, and Tregs. PD-1 is expressed on activated T and B lymphocytes, plays a pivotal role in down regulating antitumor immune responses (42) , and is operational within GBM patients (43, 44) . We found that FGL2 induces PD-1 expression on CD45 + lymphocytes compounding glioma-mediated immune suppression. Furthermore, we found that FGL2 increased the number of MDSCs in glioma tissues. MDSCs can promote tumor development via T-cell suppression-dependent and -independent mechanisms (45) . In human GBM, expanded populations of circulating MDSCs have been observed (46) . Our studies show that the increase in MDSCs was not suppressed in FcγRIIB -/-mice, suggesting that this FGL2-mediated induction is independent of CD39 and PD-1 induction by FGL2. Although the FGL2-engineered gliomas had no effect on nTreg (natural Treg) number (data not shown), the number of CD39 + Tregs increased. This increase in CD39 + Tregs cells has been previously documented in human malignant gliomas (35, 47) and CD39 -/-Tregs possess a reduced immune suppressive capacity (38) . Furthermore, the suppressive function of Tregs has previously been shown to be abolished in FGL2 -/-mice (30). Reciprocally, FGL2, CD73, CD39, and CTLA-4 are upregulated by Foxp3 in Tregs (48) . Cumulatively, these prior reports are consistent with FGL2 being a key hub of tumor-mediated immune suppression.
Limitations of the current study are that the exact mechanisms of immune suppression induced by FGL2, such as the signal pathway, were not examined and a therapeutic product will require further development. A humanized antihuman FGL2 antibody with a blocking effect will be needed for clinical application. The immune-regulatory effects of FGL2 on glioma progression have not been examined; however, anti-FGL2 treatment appears to be a promising strategy-especially given the role of FGL2 in glioma-mediated immune suppression. It is well known that cancers evade immune surveillance by exploiting a series of immune editing mechanisms to evade immune detection and eradication (49, 50) . One important mechanism is to hijack an immune cell's intrinsic checkpoints and/or subvert the immune system to be tumor supportive and/or propagative. Blocking FGL2 has therapeutic promise for cancer immunotherapy based on its role as a global mediator of tumor-mediated immune suppression.
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